Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-08-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司为境外控股公司获取银行授信提供反担保的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd providing counter-guarantees for its overseas subsidiaries to obtain bank credit. It includes detailed financial data, descriptions of the guarantee agreements, board and supervisory committee opinions, and independent director opinions. The document is not a full annual or interim report but a specific regulatory disclosure related to a financing guarantee. It is not a simple announcement or a certification but a substantive report on a financial guarantee matter. This fits best under the category of Capital/Financing Update (CAP), as it concerns updates on financing activities and guarantees related to capital structure and credit facilities.
2020-08-26 Chinese
累积投票制度实施细则
Governance Information Classification · 95% confidence The document is titled as "深圳华大基因股份有限公司 累积投票制度实施细则" which translates to "Implementation Rules for Cumulative Voting System" for the company Shenzhen BGI Genomics Co., Ltd. The content details the rules and procedures for cumulative voting in shareholder meetings, including candidate notifications, voting methods, and election rules for directors and supervisors. It references company governance, shareholder voting rights, and legal compliance with company law and securities law. There is no financial data, earnings information, or report publication mentioned. The document is a governance-related procedural document about shareholder voting and board elections, which fits the category of Governance Information (CGR). The document length is 2384 characters, which is relatively short but contains substantive governance rules rather than just an announcement. Therefore, the best classification is Governance Information (CGR).
2020-08-26 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '深圳华大基因股份有限公司 对外投资管理制度' which translates to 'Shenzhen BGI Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the principles, decision-making procedures, implementation, management, and recovery/transfer of external investments by the company. It references company laws, internal governance, and investment approval thresholds. There is no indication that this is a financial report, earnings release, regulatory filing, or announcement. It is a governance-related document describing internal rules and procedures for investment management. Therefore, it fits best under Governance Information (CGR). The document length is 4345 characters, which is substantive and contains detailed policy content, not a brief announcement or certification.
2020-08-26 Chinese
关于开展外汇衍生品交易业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the approval and commencement of foreign exchange derivative trading business. It details the board meeting resolutions, risk analysis, risk control measures, accounting policies, and the impact of the new business activity. The document is dated August 27, 2020, and includes statements from the board, independent directors, and the supervisory board. It does not contain financial statements or detailed financial performance data but rather informs shareholders and the public about a new business activity approved by the board. The document length is 3833 characters, which is relatively short and consistent with an announcement rather than a full report. It is not a financial report, earnings release, or management discussion but a regulatory announcement about a new business activity and related approvals. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-08-26 Chinese
关于增加2020年度日常关联交易预计额度的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the increase in the estimated amount of daily related-party transactions for the year 2020. It includes extensive information about the related parties, transaction categories, pricing policies, and financial data of related entities. The content focuses on disclosures about related-party transactions, their necessity, and compliance with stock exchange rules. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a call transcript, nor a management or investor presentation. The document is regulatory in nature, providing detailed disclosure about related-party transactions as required by stock exchange regulations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2020-08-26 Chinese
关于为境外控股公司获取银行授信提供反担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Shenzhen BGI Genomics Co., Ltd. regarding the provision of counter-guarantees for bank credit facilities obtained by its overseas subsidiaries. It details the board and supervisory meetings approving the guarantee, the financial status of the guarantor and the guaranteed parties, and the procedural compliance including independent director opinions and sponsor verification. The document is not a financial report, earnings release, or management discussion but a regulatory announcement about a financing-related guarantee arrangement requiring shareholder approval. It does not contain financial statements or detailed financial analysis but focuses on the guarantee and approval process. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees for credit facilities.
2020-08-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.